EC approves Biogen's ZURZUVAE as first oral treatment for postpartum depression
PositiveFinancial Markets

The European Commission has approved Biogen's ZURZUVAE, marking a significant milestone as the first oral treatment for postpartum depression. This approval is crucial as it provides a new option for mothers experiencing this condition, which can severely impact their well-being and that of their families. With ZURZUVAE, patients may find relief in a more convenient form, potentially improving adherence to treatment and overall outcomes.
— Curated by the World Pulse Now AI Editorial System